Trial · NCT03564340
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
NCT03564340, Phase 1, Phase 2, Recruiting, Regeneron Pharmaceuticals
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers. Trials, record NCT03564340. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03564340
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- NCT number
- NCT03564340
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 890 participants, estimated
- Lead sponsor
- Regeneron Pharmaceuticals
- Conditions
- Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer, Endometrial Cancer, Low-grade Serous Ovarian Cancer
- Interventions
- Ubamatamab, Cemiplimab, Sarilumab, Tocilizumab
- First posted
- 2018-06-20
- Last updated
- 2026-09-25
- Other registries' IDs
- eudract:2019-003298-24
Source ClinicalTrials.gov
Registered outcomes66
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants with Dose-limiting toxicity (DLTs) for ubamatamab monotherapy | From Cycle 1, Day 1 up to 35 days | Dose Escalation Phase |
| Primary | Number of participants with DLTs for ubamatamab with cemiplimab | From Cycle 2, Day 1 up to 21 days | Dose Escalation Phase |
| Primary | Number of participants with Treatment-emergent adverse event (TEAE)s (including immune-related adverse events (imAEs)) for ubamatamab monotherapy | Up to 2 years | Dose Escalation Phase |
| Primary | Number of participants with TEAEs (including imAEs) for ubamatamab with cemiplimab | Up to 2 years | Dose Escalation Phase |
| Primary | Number of participants with serious adverse events (SAEs) for ubamatamab monotherapy | Up to 2 years | Dose Escalation Phase |
| Primary | Number of participants with SAEs for ubamatamab with cemiplimab | Up to 2 years | Dose Escalation Phase |
| Primary | Number of deaths for ubamatamab monotherapy | Up to 2 years | Dose Escalation Phase |
| Primary | Number of deaths for ubamatamab with cemiplimab | Up to 2 years | Dose Escalation Phase |
| Primary | Number of participants with laboratory abnormalities (grade 3 or higher per Common Terminology Criteria for Adverse Events [CTCAE]) for ubamatamab monotherapy | Up to 2 years | Dose Escalation Phase |
| Primary | Number of participants with laboratory abnormalities (grade 3 or higher per CTCAE) for ubamatamab with cemiplimab | Up to 2 years | Dose Escalation Phase |
1 to 10 of 66Source ClinicalTrials.gov
See all 66 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 39652449 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03564340
GET https://conductscience.org/api/trials/v1/NCT03564340/registered?page=2